Summary
As many as 1 in 5 patients may not lose significant weight with GLP-1 drugs like Wegovy and Ozempic, despite their popularity and effectiveness in clinical trials.
Experts attribute this variability to genetic, hormonal, and brain-based differences in regulating energy, as well as factors like sleep apnea or medications that hinder weight loss.
Non-responders often face frustration, but doctors stress alternative options, including different medications, lifestyle adjustments, or older treatments.
I wonder if they will respond better to retatrutide, since it’s a glucagon triple agonist.